Medical News

RSS

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

Abbott today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new FreeStyle Lite blood glucose test strips. The new FreeStyle Lite test strips minimize interference during blood glucose testing and are designed to offer a better testing experience.

24 May 2010

Baxa announces release of InFuse T-10 Syringe Infuser

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of the InFuse T-10 Syringe Infuser. Specifically designed for the delivery of intermittent antibiotics and other non-rate critical intravenous doses, the Baxa InFuse T-10 Syringe Infuser frees up expensive, smart infusion pumps for more critical applications and gives nurses more time to focus on patient care.

24 May 2010

Scientists develop DNA-vaccine that restricts supply of blood to tumours

A DNA-vaccine that restricts the supply of blood to tumours has been developed by scientists at the Swedish medical university Karolinska Institutet. The vaccine slows the growth of breast cancer tumours in mice.

24 May 2010

Vaso Healthcare, GE Healthcare sign sales representative agreement

Vasomedical, Inc. today announced that its subsidiary, Vaso Diagnostics Inc. d/b/a Vaso Healthcare, has signed a sales representative agreement with GE Healthcare, the healthcare business unit of GE, for the sale of select GE Healthcare Diagnostic Imaging products. Under the Agreement, Vaso Healthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and District of Columbia.

24 May 2010

Research work holds promise for biological substitute for dental implants

A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.

24 May 2010

Somanetics' Vital Sync bedside monitor system receives FDA clearance

Somanetics Corporation announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to expand features on its Vital Sync bedside monitor and research data aggregation system. The clearance allows for interface with a broader range of bedside devices, display of derived parameters of calculated clinical indices, and an automated events trigger to alert clinicians when patient parameters fall outside desired thresholds.

24 May 2010

Sinapis Pharma completes Bridge financing to continue support drug development program

Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.

24 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

Hospitals facing new payment squeezes

News outlets report on payment issues for hospitals, including those stemming from the new health law.

24 May 2010

2010 Southeast Michigan Mid-Market Group Benefits Survey released

McGraw Wentworth, Michigan's largest employee group benefit brokerage/consulting firm, today released the results of its 2010 Southeast Michigan Mid-Market Group Benefits Survey. The annual survey, now in its seventh year, tracks health benefits and trends for 2010 among 414 southeast Michigan organizations with 100-10,000 employees.

24 May 2010

FDA clears Simplexa Influenza A H1N1 (2009) test

The U.S. Food and Drug Administration today announced it has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 Influenza Virus in patients with signs and symptoms of respiratory infection.

24 May 2010

Today's OpEds: Taxing health plans, a health care 'loophole,' NY Times on medical loss ratio

Few Americans know what a "medical loss ratio" is, but a fierce struggle over how to calculate it under the new health care reform law will determine how much insurers must spend on patient care and how much they can retain for administration and profits. This is but one of many battles that will emerge as federal and state regulators develop regulations to implement reform (5/23).

24 May 2010

Dialog Medical becomes newest Affinity Program Partner of AUA

Dialog Medical, the leading provider of informed consent and patient education systems for physician practices and hospitals, today announced that it has become the newest Affinity Program Partner of the American Urological Association.

24 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

Lawmakers could vote this week on three-year 'doc fix,' COBRA subsidy extension

Before they leave for the Memorial Day recess, lawmakers face legislation which includes a provision on Medicare payments to physicians and an extension of the COBRA subsidy to newly laid-off workers.

24 May 2010

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

According to a new survey sponsored by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect. This positive relationship is particularly important in treating schizophrenia as patients and psychiatrists must work closely together to determine appropriate treatment plans that will help patients manage their symptoms and reduce their risk of relapse.

24 May 2010

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.

24 May 2010

Study: Health law could mean penalties for one in three employers

News outlets covered analyses of health law provisions affecting businesses. "About one-third of employers subject to major requirements of the new health care law may face tax penalties because they offer health insurance that could be considered unaffordable to some employees, a new study says," The New York Times reports.

24 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010